 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
| 5 | 1/1 | 返回列表 |
| 查看: 1371 | 回復(fù): 17 | |||
| 當(dāng)前只顯示滿足指定條件的回帖，點(diǎn)擊這里查看本話題的所有回帖 | |||
[交流]
開發(fā)一種新藥的驚人花費(fèi)（The truly staggering cost of inventing new drugs）
|
|||
|
原文鏈接：http://bioluminor.biomart.cn/news/2770272.htm During the Super Bowl, a representative of the pharmaceutical company Eli Lilly posted the on the company’s corporate blog that the average cost of bringing a new drug to market is $1.3 billion, a price that would buy 371 Super Bowl ads, 16 million official NFL footballs, two pro football stadiums, pay of almost all NFL football players, and every seat in every NFL stadium for six weeks in a row. This is, of course, ludicrous. The average drug developed by a major pharmaceutical company costs at least $4 billion, and it can be as much as $11 billion. The drug industry has been tossing around the $1 billion number for years. It is based largely on a study (supported by drug companies) by Joseph DiMasi of Tufts University. It’s a nice number for the pharmaceutical industry, because it seems to justify the idea that medicines should be pricey (and increasingly, they can be very pricey, costing tens of thousands of dollars per patient per year) without making it seem that inventing new medicines is so expensive an endeavor as to be ultimately futile. But as Bernard Munos of the InnoThink Center for Research In Biomedical Innovation has noted, just adjusting that estimate for current failure rates results in an estimate of $4 billion in research dollars spent for every drug that is approved. But Munos showed me another figure, where he divided each drug company’s R&D budget by the average number of drugs approved. This was far more dramatic. The range of money spent is stunning. AstraZeneca has spent $12 billion in research money for every new drug approved, as much as the top-selling medicine ever generated in annual sales; Amgen spent just $3.7 billion. At $12 billion per drug, inventing medicines is a pretty unsustainable business. At $3.7 billion, you might just be able to make money (a new medicine can probably keep generating revenue for ten years; invent one a year at that rate and you’ll do well). There are lots of expenses here. A single clinical trial can cost $100 million at the high end, and the combined cost of manufacturing and clinical testing for some drugs has added up to $1 billion. But the main expense is failure. AstraZeneca does badly by this measure because it has had so few new drugs hit the market. Eli Lilly spent roughly the same amount on R&D, but got twice as many new medicines approved over that 15 year period, and so spent just $4.5 billion per drug. Wanting to make this even more rigorous, Forbes (that would be Scott DeCarlo and me) took Munos’ count of drug approvals for the major pharmas and combined it with their research and development spending as reported in annual earnings filings going back fifteen years, pulled from a Thomson Reuters database using FactSet. We adjusted all the figures for inflation. Using both drug approvals and research budgets since 1997 keeps the estimates being skewed by short-term periods when R&D budgets or drug approvals changed dramatically. The range of money spent is stunning. AstraZeneca has spent $12 billion in research money for every new drug approved, as much as the top-selling medicine ever generated in annual sales; Amgen spent just $3.7 billion. At $12 billion per drug, inventing medicines is a pretty unsustainable business. At $3.7 billion, you might just be able to make money (a new medicine can probably keep generating revenue for ten years; invent one a year at that rate and you’ll do well). There are lots of expenses here. A single clinical trial can cost $100 million at the high end, and the combined cost of manufacturing and clinical testing for some drugs has added up to $1 billion. But the main expense is failure. AstraZeneca does badly by this measure because it has had so few new drugs hit the market. Eli Lilly spent roughly the same amount on R&D, but got twice as many new medicines approved over that 15 year period, and so spent just $4.5 billion per drug. |
回復(fù)此樓» 猜你喜歡
生物組織中有目標(biāo)分析物，專屬性怎么做
已經(jīng)有0人回復(fù)
-
2026申博推薦
已經(jīng)有1人回復(fù)
-
藥物學(xué)論文潤色/翻譯怎么收費(fèi)?
已經(jīng)有260人回復(fù)
-
一篇擴(kuò)散模型的Nature Machine Intelligence論文和Elsevier上的深度學(xué)習(xí)藥物書籍
已經(jīng)有1人回復(fù)
-
中國藥科大學(xué)2026入學(xué)博士，藥物合成和設(shè)計(jì)經(jīng)驗(yàn)，放射化學(xué)及放射醫(yī)學(xué)研究
已經(jīng)有25人回復(fù)
-
使用MolAICal進(jìn)行多肽虛擬篩選教程-同樣適用于蛋白質(zhì)和核酸的虛擬篩選
已經(jīng)有1人回復(fù)
-
使用MolAICal計(jì)算藥物化學(xué)過濾器MCFs及MCE-18描述符
已經(jīng)有0人回復(fù)
-
使用MolAICal發(fā)現(xiàn)蛋白受體潛在的活性口袋及位點(diǎn)
已經(jīng)有0人回復(fù)
-
華理藥學(xué)學(xué)碩求調(diào)劑，總分324
已經(jīng)有0人回復(fù)
-
澳門理工大學(xué)人工智能藥物發(fā)現(xiàn)中心招收2026級博士研究生（申請-考核制）
已經(jīng)有10人回復(fù)
» 搶金幣啦！回帖就可以得到:
-
電力全國重點(diǎn)實(shí)驗(yàn)室雙一流A類長江學(xué)者團(tuán)隊(duì)招2026年全日制博士1名（4月3日截止）
+2/96
-
南京醫(yī)科大學(xué)生殖醫(yī)學(xué)與子代健康國重實(shí)驗(yàn)室-董飛宏課題組-學(xué)術(shù)碩士招生
+1/93
-
材料、化學(xué)類碩士研究生調(diào)劑機(jī)會，學(xué)碩專碩均可，有意請聯(lián)系，非誠勿擾！
+1/84
-
天津理工大學(xué)國家杰青王鐵課題組招收2026年博士研究生
+1/82
-
雙一流南京醫(yī)科大學(xué)招計(jì)算機(jī)、AI、統(tǒng)計(jì)、生物信息等方向26年9月入學(xué)博士
+1/80
-
福建農(nóng)林大學(xué)材料工程學(xué)院高分子材料課題組招生
+1/79
-
光學(xué)工程學(xué)碩調(diào)劑信息
+2/42
-
哈爾濱工業(yè)大學(xué)（深圳）-何自開教授團(tuán)隊(duì)誠招化學(xué)工程與技術(shù)專業(yè)博士研究生
+1/40
-
招收材料、化學(xué)類調(diào)劑生，專碩學(xué)碩均可
+1/39
-
招收2026年材料與化工專碩調(diào)劑，山東省屬重點(diǎn)大學(xué)，過國家線即可調(diào)劑，名額充足
+2/38
-
0854電子信息調(diào)劑，閩南師大光電芯片研發(fā)實(shí)驗(yàn)室，柯少穎教授課題組，集成電路
+1/35
-
湖北工業(yè)大學(xué) 生命科學(xué)與健康學(xué)院 課題組招收2026級食品/生物方向碩士
+1/29
-
春眠不覺曉
+1/23
-
雙一流湘潭大學(xué)化工學(xué)院招收化工、能源動力、工程熱物理相關(guān)研究生調(diào)劑
+1/18
-
[求調(diào)劑]鄭州大學(xué)生物技術(shù)專業(yè) 一志愿浙大生科院340分
+1/7
-
青島科技大學(xué)化工學(xué)院院士團(tuán)隊(duì)2026年擬招收全日制博士研究生1名
+1/6
-
26年申博自薦-計(jì)算機(jī)視覺
+1/5
-
武漢紡織大學(xué)紡織纖維及制品教育部重點(diǎn)實(shí)驗(yàn)室招收博士研究生
+1/2
-
湘潭大學(xué)教師招聘
+1/2
-
福建師范大學(xué)海峽柔性電子學(xué)院2026年9月入學(xué)博士-有機(jī)化學(xué)-申請考核制
+1/1
9樓2015-09-01 08:14:29
7樓2015-08-31 16:02:44
10樓2015-09-01 08:19:15
11樓2015-09-14 11:50:36
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 一志愿武理材料工程348求調(diào)劑 +5 | ￣^￣゜汗 2026-03-19 | 7/350 |
|
|---|---|---|---|---|
|
[考研] 環(huán)境學(xué)碩288求調(diào)劑 +6 | 皮皮皮123456 2026-03-22 | 6/300 |
|
|
|
[考研] 一志愿 西北大學(xué) ，070300化學(xué)學(xué)碩，總分287，雙非一本，求調(diào)劑。 +3 | 晨昏線與星海 2026-03-20 | 3/150 |
|
|
|
[考研] 0856材料專碩353求調(diào)劑 +4 | NIFFFfff 2026-03-20 | 4/200 |
|
|
|
[考研] 286分人工智能專業(yè)請求調(diào)劑愿意跨考！ +4 | lemonzzn 2026-03-17 | 8/400 |
|
|
|
[考研] 280求調(diào)劑 +11 | 咕嚕曉曉 2026-03-18 | 12/600 |
|
|
|
[考研] 333求調(diào)劑 +5 | 87639 2026-03-21 | 7/350 |
|
|
|
[考研] 一志愿南大，0703化學(xué)，分?jǐn)?shù)336，求調(diào)劑 +3 | 收到VS 2026-03-21 | 3/150 |
|
|
|
[考研] 297求調(diào)劑 +3 | 喜歡還是不甘心 2026-03-20 | 3/150 |
|
|
|
[考研] 材料與化工（0856）304求 B區(qū) 調(diào)劑 +3 | 邱gl 2026-03-21 | 3/150 |
|
|
|
[考研] 316求調(diào)劑 +6 | 梁茜雯 2026-03-19 | 6/300 |
|
|
|
[考研] 一志愿華中科技大學(xué)，080502，354分求調(diào)劑 +5 | 守候夕陽CF 2026-03-18 | 5/250 |
|
|
|
[考研]
 271材料工程求調(diào)劑
+8
|
.6lL 2026-03-18 | 8/400 |
|
|
|
[考研] 274求調(diào)劑 +10 | S.H1 2026-03-18 | 10/500 |
|
|
|
[考研] 290求調(diào)劑 +7 | ^O^乜 2026-03-19 | 7/350 |
|
|
|
[考研] 353求調(diào)劑 +3 | 拉鉤不許變 2026-03-20 | 3/150 |
|
|
|
[考研] 材料工程專碩調(diào)劑 +5 | 204818@lcx 2026-03-17 | 6/300 |
|
|
|
[考研] 344求調(diào)劑 +6 | knight344 2026-03-16 | 7/350 |
|
|
|
[考研] 301求調(diào)劑 +4 | A_JiXing 2026-03-16 | 4/200 |
|
|
|
[考研] [導(dǎo)師推薦]西南科技大學(xué)國防/材料導(dǎo)師推薦 +3 | 尖角小荷 2026-03-16 | 6/300 |
|